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n INTRODUCTION
Echocardiographic studies have identifieda pericardial effusion in approximately 20per cent (range 10 to 40 per cent) of pa-
tients with AIDS [1-3]. In many cases pericardi-
tis has a brief and self-limiting course. On the
other hand, treatment of pericarditis remains
largely empirical owing to a relative lack of ran-
domized controlled trials and NSAIDs (non-
steroidal inflammatory drugs) are the most
credited option [4]. Indomethacin is a widely
used NSAID and inhibits the activity of cy-
cloxygenase by decreasing the formation of the
precursors of prostaglandins and thrombox-
anes from arachidonic acid or by activating per-
oxisome-proliferator activated receptors. 
Indomethacin is generally considered safe and
well tolerated but it can provoke acute intersti-
tial nephritis and acute renal failure due to a de-
creased prostaglandin synthesis and renal is-
chemia. In healthy adult patients the incidence
of renal adverse effects is less than 1% and the
risk increases with age because of concomitant
renal disease, diabetes, diuretics and congestive
heart failure [5]. Indomethacin-induced renal
failure is usually reversible after the drug is
stopped [6-10]. Rare cases of indomethacin-in-
duced hepatitis, cholestasis and jaundice have
been reported and several studies carried out
on animals show the hepatic toxicity of in-
domethacin [11, 12]. We describe a case of acute
renal failure and cholestatic hepatitis following
therapy with indomethacin in a patient with
AIDS and pericarditis starting HAART (highly
active antiretroviral therapy).
n CASE REPORT
A 54-year-old man was admitted to our Infec-
tious Diseases Department of the University
Hospital of Palermo in September 2012 because
of fever and chest pain. He was an MSM and
had experienced a 40 kg weight loss during the
previous year. His clinical history was unre-
markable, except for a bipolar disorder. On
physical examination he had oral candidiasis
and paraphonic tones all over the precordium.
On neurological examination he presented
bradylalia and psychomotor slowing. 
On admission ELISA anti-HIV serology and
Western Blot test were performed and HIV in-
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fection was diagnosed. An electrocardiograph-
ic exam showed sinus tachycardia (PR 100
bpm), isolated ventricular ectopic beats, PR in-
terval upper reference limits and abnormal re-
polarization. Pericardial effusion was evident
on echocardiographic exam and pericarditis
without haemodynamic impairment was diag-
nosed. Indomethacin (50 mg TID) was adminis-
tered. Upon admission the CD4 T-cell count
was 2/mmc (1.41%) and HIV-RNA 588,000
copies/ml. Antiretroviral treatment with
darunavir/ritonavir 800/100 mg once a day
and tenofovir/emtricitabine and prophylaxis
for OIs with cotrimoxazole and azitromycin
was started. Serology for syphilis, toxoplasmo-
sis, B and C hepatitis resulted negative and re-
nal and liver function were within normal val-
ues (GOT/GPT 13/11 U/L; total and direct
bilirubin respectively 0.35 and 0.22 mg/dl, cre-
atinine 0.91 mg/dl, BUN 34 mg/dl, GFR 120
ml/min/1.73 m2). White cells blood count was
1700/mmc, haemoglobin was 8.2 g/dl and
platelets were 110,000/mm3.
A few days after admission fever and chest pain
disappeared and we observed a mild reduction
of pericardial effusion on echocardiography
and electrocardiographic normalization but the
patient developed watery diarrhoea without
mucus or blood. The direct faecal exam re-
vealed the presence of Cryptosporidium spp.
Clinical conditions and laboratory tests pro-
gressively worsened and liver and renal dys-
function appeared (total and direct bilirubin
12.4/11.13 mg/dL, creatinine 2.37 mg/dL,
BUN 104 mg/dL, GFR 30 mL/min/1.73 m2).
HAART with tenofovir/emtricitabine was re-
placed with lamivudine and raltegravir and
boosted darunavir was continued but renal and
liver function rapidly plummeted (total and di-
rect bilirubin 16.65/14.31 mg/dL, creatinine
5.42 mg/dL, BUN 232 mg/dL, alkaline phos-
phatase 516 mg/dL). Indomethacin was sus-
pended and the patient had to receive dialysis.
During the remaining hospitalization a liver
function improvement (total and direct biliru-
bin 3.59/2.96 mg/dL) was observed but renal
dysfunction was irreversible despite dialysis.
n DISCUSSION
Severe renal impairment becomes a major con-
cern in patients with HIV infection above all if
they are assuming antiretroviral treatment con-
taining tenofovir. Tenofovir has been associat-
ed with chronic renal dysfunction and Fanconi
syndrome, especially in the setting of multifac-
torial causes for renal damage or in patients
with underlying renal disease [13]. In the litera-
ture, to date, four cases of acute renal failure in
patients assuming tenofovir and NSAIDs have
been described but all of them presented other
important factors of renal dysfunction [14]. Sev-
eral NSAIDs have been associated with liver
damage as well [15]. Our patient did not have
other risk factors for renal damage apart from
HIV infection and an antiretroviral treatment
including tenofovir administration seemed the
most appropriate choice. In spite of this he ex-
perienced at the same time acute renal failure
and cholestatic hepatitis probably due to a
drug-drug interaction between antiretroviral
drugs, antibiotics used for OI prophylaxis and
indomethacin. Dehydration occurring during
Cryptosporidium spp enteritis probably con-
tributed to reduced renal perfusion and to last-
ing damage. Based on this case we think more
attention should be paid when several drugs
are used in this kind of patient and a dose ad-
justment could be necessary to avoid rapid life-
threatening renal deterioration.
Keywords: indomethacin, tenofovir, acute renal
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The most frequent clinical manifestation of cardio-
vascular diseases in patients with AIDS is peri-
carditis. Indomethacin is a well tolerated non-
steroidal inflammatory drug (NSAID) widely used
in the treatment of pericarditis but it can provoke
acute renal failure. Tenofovir has also been associ-
ated with chronic renal dysfunction. Liver damage
can occur during treatment with NSAIDs. We de-
scribe the first case of acute renal failure and
cholestatic hepatitis occurring in an HIV-naïve pa-
tient with pericarditis starting HAART (highly ac-
tive antiretroviral therapy) and assuming in-
domethacin and antibiotic therapy for opportunis-
tic infections (OIs) at the same time. Based on our
case we suggest that attention be paid to drug-
drug interactions in such patients.
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La pericardite è la più frequente manifestazione
clinica a carico dell’apparato cardiovascolare nei
pazienti con AIDS. L’indometacina è un farmaco
antinfiammatorio non steroideo (FANS) ben tolle-
rato e ampiamente usato nella terapia della peri-
cardite ma può causare insufficienza renale acuta
(IRA). Anche il tenofovir è stato associato alla com-
parsa di danno renale. L’aumento degli indici di
funzionalità epatica è stato descritto in corso di te-
rapia con FANS. Il nostro è il primo caso clinico ri-
portato di IRA ed epatite colestatica in un pazien-
te HIV-naïve con pericardite che iniziava la terapia
antiretrovirale e assumeva allo stesso tempo indo-
metacina e terapia antibiotica per la profilassi del-
le infezioni opportunistiche. Sulla base della nostra
esperienza, molta cautela deve essere posta nella
gestione delle interazioni farmacologiche in questo
tipo di pazienti.
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